Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Review ArticleProceedings of the Joint International Symposium “Vitamin D in Prevention and Therapy” and “Biologic Effects of Light”, 5-7 June, 2019 (Homburg/Saar, Germany)R

Vitamin D in Preclinical Models of Fatty Liver Disease

ERSIN KARATAYLI, CAROLINE S. STOKES and FRANK LAMMERT
Anticancer Research January 2020, 40 (1) 527-534; DOI: https://doi.org/10.21873/anticanres.13981
ERSIN KARATAYLI
Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ersin.karatayli@uks.eu
CAROLINE S. STOKES
Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRANK LAMMERT
Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Simple steatosis in non-alcoholic fatty liver disease (NAFLD) progresses to non-alcoholic steatohepatitis (NASH) when excessive fat accumulation is accompanied by ballooning, inflammation, and progressive hepatocellular injury. Due to the increasing global incidence of NAFLD/NASH and the lack of effective drugs, current treatment options are currently dominated by lifestyle interventions, including dietary and physical activity modifications. In this regard, vitamin D has received widespread attention in recent years. In line with its pleiotropic physiological effects, preclinical animal models and patient cohorts have demonstrated anti-inflammatory, anti-fibrotic and anti-proliferative effects of vitamin D on NAFLD and NASH. Several animal models have confirmed the association of vitamin D deficiency and NALFD/NASH severity in humans and revealed potential benefits of dietary vitamin D supplementation. These preclinical models also provide critical guidance to define the roles and therapeutic potential of vitamin D as well as its downstream functional mechanisms in the pathogenesis of fatty liver disease. This review summarizes vitamin D research in currently available animal models of fatty liver disease.

  • Animal models
  • vitamin D
  • non-alcoholic fatty liver disease
  • non-alcoholic steatohepatitis
  • review

Non-alcoholic steatohepatitis (NASH) was first introduced to medical terminology by Ludwig et al. in 1980 to describe an unknown liver disease that histologically mimics alcoholic fatty liver disease in patients with no history of alcohol abuse (1). Since then, increasing evidence has demonstrated that NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), which is distinct from simple fatty liver (hepatic steatosis), since it is characterized by necro-inflammation, hepatocellular ballooning and progressive tissue damage in addition to hepatic fat deposition, which may lead to liver cirrhosis and hepatocellular carcinoma. Due to the global increasing incidence of NAFLD/NASH (2) and limited therapeutic options, lifestyle modifications such as increased physical activity and dietary-related interventions remain important treatment strategies (3). Currently, vitamin D, with its direct anti-inflammatory, anti-proliferative and anti-fibrotic effects shown in experimental studies (4, 5), is a promising nutrient for the treatment of NAFLD/NASH, since it is commonly deficient in chronic liver diseases (6). Moreover, vitamin D has been reported to be associated with NAFLD/NASH in several epidemiological studies (7, 8). Longitudinal cohort studies and randomized controlled trials offer ideal methodological designs to confirm these protective effects of vitamin D on liver diseases (9). However, such clinical trials are to a great extent hampered by the slow nature of disease progression (10) and the wide spectrum of disease stages of NAFLD/NASH, which are difficult to differentiate non-invasively (11). Hence, various animal models of fatty liver disease that mimic human pathobiology have been developed for vitamin D research. As summarized in Table I, these preclinical models largely depend on diet-induced liver injury, however a limited number of chemically induced and alcohol-induced fatty liver disease models are also listed as well as those that depend on the genetic background of the animals. The aim of this review is to present an overview of vitamin D research in current experimental fatty liver disease models to better understand the role and therapeutic potential of vitamin D and its effects on the pathogenesis and the course of the disease.

Vitamin D in Fatty Liver Disease

Vitamin D is a fat-soluble secosteroid that is metabolized in the liver and kidney and is converted to the 1,25(OH)2D3 active form (calcitriol) in the body (Figure 1). As calcitriol, vitamin D acts as a sterol hormone that regulates diverse biological events, ranging from host immune responses to cellular differentiation in addition to its classical role in calcium and bone metabolism (12). Therefore, it is not surprising that a growing body of evidence links vitamin D deficiency (VDD) with multiple inflammatory (13) and chronic disorders (14), including chronic liver diseases (15). In this regard, various studies have demonstrated that VDD is more common and associated with the severity and disease progression in patients with NAFLD/NASH (16-22). Although two meta-analyses (7, 8) and a recent study in a large cohort of Korean patients with NAFLD (23) confirmed these findings, it is noteworthy to state that several studies have presented contradictory results with no significant association between serum vitamin D concentrations and fatty liver disease phenotypes (24-27). These controversies may be, at least in part, explained by the heterogeneity of the criteria used for NAFLD diagnosis and VDD, as well as differences in vitamin D assays. Nevertheless, future prospective randomized clinical trials in patients with NAFLD/NASH can be envisioned.

View this table:
  • View inline
  • View popup
Table I.

Vitamin D research in preclinical models of fatty liver disease.

Vitamin D Research in Preclinical Models of Fatty Liver Disease

Given the conflicting results in human studies, animal models of fatty liver disease gain more importance when it comes to the potential to provide critical guidance in delineating causal roles and the therapeutic potential of vitamin D on disease pathogenesis and progression. Several in vivo and in vitro studies have revealed that vitamin D and its receptor (VDR) are involved in repressing hepatic stellate cell (HSC) activation, thereby inhibiting the primary driver of hepatic fibrogenesis (4, 28, 29). Consistent with these findings, we have demonstrated that low-vitamin D diet-fed Abcb4 knock-out mice develop more advanced biliary fibrosis and elevated collagen deposition (30). Feeding these mice a high-vitamin D diet led to an increase in serum vitamin D concentrations, which simultaneously lowered liver enzyme activities, altered the expression levels of profibrogenic genes, and ameliorated, in part, liver injury. A more recent in vitro study has further confirmed the inhibition of HSC activation by vitamin D through transforming growth factor (TGF)-β signaling in primary human HSC, supporting the anti-fibrotic effect of vitamin D (31).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Vitamin D synthesis and activation. Cholesterol is metabolized to 7-dehydrocholesterol (7-DHC) in liver, which is further converted to vitamin D3 (cholecalciferol, an inactive form of vitamin D) in the skin when exposed to UVB radiation via sunlight. In addition to photosynthesis, vitamin D is also acquired by dietary intake and supplementation, entering the blood stream after intestinal absorption. Vitamin D is then converted to 1,25(OH)2D3 (active form) through sequential hydroxylation steps in liver and kidney. 7-DHC: 7-dehydrocholesterol; 25(OH)D3: 25-hydroxyvitamin D3 (calcidiol); 1,25(OH)2D3: 1,25 dihydroxyvitamin D3 (calcitriol, active form of vitamin D); UVB: ultraviolet radiation in wavelength region B (320-290 nm).

Su et al. (32) have demonstrated that feeding BALB/c male mice a vitamin D-deficient, high fat diet resulted in overt insulin resistance and NASH phenotypes with aggravated systemic and local inflammation, whereas sufficient vitamin D supplementation ameliorated the histopathological changes with less insulin resistance and moderate hepatic steatosis. This study also revealed a critical role of the vitamin D/VDR axis in suppressing NASH progression by maintaining intestinal integrity through the induction of defensins and tight junction genes. Similarly, a recent study has reported the reduction of tumor necrosis factor (TNF)-α-mediated immunological abnormalities and hepatic steatosis in a high fat diet rodent model of NASH with chronic calcitriol supplementation (33). Another experimental study has demonstrated that VDD plus high fat diet impairs the enterohepatic circulation of bile acids, resulting in NASH in BALB/c inbred mice via repression of the ileal apical sodium-dependent bile acid cotransporter [Asbt=Solute carrier 10A2 (Slc10a2)] (34). Of note, the NASH phenotype was corrected by administration of calcitriol, which restored ileal Slc10a2 expression and reduced hepatic inflammation and steatosis. In line with these findings, Han et al. (35) have demonstrated that 1,25(OH)2D3 supplementation in rats with NASH induced by choline-deficient diet resulted in the reduction of cytokeratin 18 apoptotic fragment M30, which is a bona fide marker for liver injury (36). Additionally, a shift of bile acid metabolism to lower cholesterol levels by down-regulation of small heterodimer protein (Shp=Nuclear receptor 0B2) and up-regulation of cholesterol 7α-hydroxylase (Cyp7a1) through intraperitoneal (IP) injections of 1,25(OH)2D3 was observed in mice on Western diet (37). Moreover, 1,25(OH)2D3 has also been shown to ameliorate hepatic steatosis by autophagy through the induction of autophagy-related-16-like 1 (Atg16l1) protein (38), the inhibition of lipogenesis and the promotion of fatty acid oxidation in vivo (39). These preventive and therapeutic effects of vitamin D have also been reported in a number of experiments using phototherapy, which increased the concentrations of active circulating vitamin D in serum (40, 41). Nakano et al. (41) have reported the suppression of apoptosis, inflammation and fibrosis in NASH models Lewis rats on choline-deficient, L-amino acid-defined and iron-supplemented diet (CDAA) as well as in obesity-related NASH (Zucker fa/fa rats). These changes were reflected by lower serum aminotransferase activities and hepatic triglyceride levels, the suppression of inflammatory and fibrotic genes such as TNF-α, TGF-β and α-Smooth muscle actin, and an increase in serum adiponectin levels. Interestingly, both skin exposure to ultraviolet radiation and the supplementation of CDAA-fed rats with 1α(OH)D3 (0.4 μg/kg orally 3 times/week) resulted in a similar phenotype. Roth et al. (42) have provided additional evidence on the immune-regulatory role of vitamin D in NAFLD in obese Sprague-Dawley rats. Liver histopathology in these rats revealed that vitamin D-depleted Western diet resulted in increased lobular inflammation and higher NAFLD activity scores, accompanied by elevated expression of hepatic resistin, interleukins (IL) 1β, 4 and 6 and Toll-like receptors (TLR) 2, 4 and 9 as well as the oxidative stress marker heme oxygenase 1 (HO-1), suggesting that VDD may lead to elevated endotoxin exposure, exacerbated inflammatory pathways, and increased oxidative stress, which subsequently aggravate NAFLD. In line with these results, suppression of TLR4-mediated inflammation and amelioration of liver injury have been observed in diabetic rats treated with 1,25(OH)2D3 (43).

Factors Involved in Vitamin D Metabolism in Experimental Models of Fatty Liver Disease

Further studies in experimental models suggest that not only vitamin D but also related factors involved in vitamin D metabolism are associated with NAFLD/NASH. Bosic et al. (44) have investigated hepatic Vdr expression in two mouse models of fatty liver disease, i.e. apolipoprotein E knock-out (Apoe−/−) mice on a high fat diet and wild-type mice on methionine and choline-deficient (MCD) diet as well as in patients with NAFLD and NASH. Similar to the mouse models, hepatic VDR expression in livers from NAFLD patients was markedly increased in the setting of hepatosteatosis, but decreased in NASH, suggesting an early role of VDR induction in the pathogenesis of fatty liver diseases. Early induction of VDR in NAFLD was also found to modulate key hepatic lipid regulatory genes with decreased expression of CD36, DGAT2, C/EBPα and FGF21, and increased expression of PNPLA2, LIPIN1 and PGC1α. Moreover, using a double knock-out ApoE−/−Vdr−/− mice, they have demonstrated that the deletion of VDR prevents diet-induced fatty liver. Convincing evidence on the key role of VDR in NAFLD pathogenesis has been provided by Ding et al. (45) in a preclinical model of Vdr−/− mice, showing that VDR ligands inhibit HSC activation by abrogating TGF-β-induced fibrotic gene signatures through a VDR/SMAD “genomic circuit”, whereas Vdr knock-out mice spontaneously develop hepatic fibrosis.

Furthermore, normalization of VDR and SMAD3 binding in the presence of both calcipotriol and TGFβ1 to their basal levels revealed that the occupancy of VDR and SMAD3 were inversely correlated, suggesting TGFβ-induced chromatin accessibility produces a genomic architecture that facilitates VDR to reverse SMAD activation.

Another factor in vitamin D metabolism, vitamin D binding protein (DBP), binds to vitamin D metabolites and acts as a reservoir, in particular for 25(OH)D (46, 47). DBP thereby helps to ameliorate VDD. Proteomics analysis in a NASH model of C57BL/6J male mice fed an MCD diet revealed DBP to be among the most differentially expressed proteins (48). Interestingly, a genome-wide association study of 928 adolescents assessed for NAFLD revealed a highly significant association of NAFLD with the single nucleotide polymorphism rs222054 in the group-specific globulin gene (GC), which encodes DBP (49). In relation to these findings, we have demonstrated that liver steatosis is associated with low serum 25(OH)D concentrations in a cohort of 241 patients with chronic liver diseases, who were assessed non-invasively by controlled attenuation parameter (CAP) to quantify hepatic steatosis (50). In addition, the rare allele of 7-dehydrocholesterol reductase (DHCR7) variant (rs12785878) has also been shown to be associated with increased liver stiffness (51). However, no associations with CAP were found for other common vitamin D pathway gene variants, namely GC rs7041, cytochrome P450 2R1 (CYP2R1) rs10741657, DHCR7 rs12785878 or VDR rs7974353 (52).

Conclusion

A growing body of evidence links abnormalities in vitamin D metabolism to fatty liver disease. Although the preclinical models in this review do not replicate the whole spectrum of human disease, they are of relevance in elucidating the roles and pathways of vitamin D and related factors involved in the pathogenesis of NAFLD and NASH, as well as for providing a better mechanistic understanding of the potential of vitamin D-based therapies. However, the utility of these models in verifying hypotheses on disease pathogenesis or intervention studies does not eliminate the need for well-designed clinical trials in (vitamin D-deficient) patients, particularly due to the broad spectrum of alterations in NAFLD.

Footnotes

  • Authors' Contributions

    All the Authors contributed in the drafting, intellectual and structural development and critical review of this manuscript.

  • Conflicts of Interest

    The Authors declare that there are no conflicts of interest regarding the publication of this article.

  • Received September 11, 2019.
  • Revision received September 23, 2019.
  • Accepted September 25, 2019.
  • Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Ludwig J,
    2. Viggiano TR,
    3. McGill DB,
    4. Oh BJ
    : Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55(7): 434-438, 1980. PMID: 7382552.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Younossi ZM,
    2. Koenig AB,
    3. Abdelatif D,
    4. Fazel Y,
    5. Henry L,
    6. Wymer M
    : Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1): 73-84, 2016. PMID: 26707365. DOI: 10.1002/hep.28431
    OpenUrlCrossRefPubMed
  3. ↵
    1. Kenneally S,
    2. Sier JH,
    3. Moore JB
    : Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: A systematic review. BMJ Open Gastroenterol 4(1): 2017-000139, 2017. PMID: 28761689. DOI: 10.1136/bmjgast-2017-000139
    OpenUrl
  4. ↵
    1. Abramovitch S,
    2. Dahan-Bachar L,
    3. Sharvit E,
    4. Weisman Y,
    5. Ben Tov A,
    6. Brazowski E,
    7. Reif S
    : Vitamin d inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 60(12): 1728-1737, 2011. PMID: 21816960. DOI: 10.1136/gut.2010.234666
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Kitson MT,
    2. Roberts SK
    : D-livering the message: The importance of vitamin d status in chronic liver disease. J Hepatol 57(4): 897-909, 2012. PMID: 22634121. DOI: 10.1016/j.jhep.2012.04.033
    OpenUrlCrossRefPubMed
  6. ↵
    1. Arteh J,
    2. Narra S,
    3. Nair S
    : Prevalence of vitamin d deficiency in chronic liver disease. Dig Dis Sci 55(9): 2624-2628, 2010. PMID: 19960254. DOI: 10.1007/s10620-009-1069-9
    OpenUrlCrossRefPubMed
  7. ↵
    1. Eliades M,
    2. Spyrou E,
    3. Agrawal N,
    4. Lazo M,
    5. Brancati FL,
    6. Potter JJ,
    7. Koteish AA,
    8. Clark JM,
    9. Guallar E,
    10. Hernaez R
    : Meta-analysis: Vitamin d and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 38(3): 246-254, 2013. PMID: 23786213. DOI: 10.1111/apt.12377
    OpenUrlCrossRefPubMed
  8. ↵
    1. Wang X,
    2. Li W,
    3. Zhang Y,
    4. Yang Y,
    5. Qin G
    : Association between vitamin d and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Results from a meta-analysis. Int J Clin Exp Med 8(10): 17221-17234, 2015. PMID: 26770315.
    OpenUrl
  9. ↵
    1. Geier A,
    2. Eichinger M,
    3. Stirnimann G,
    4. Semela D,
    5. Tay F,
    6. Seifert B,
    7. Tschopp O,
    8. Bantel H,
    9. Jahn D,
    10. Marques Maggio E,
    11. Saleh L,
    12. Bischoff-Ferrari HA,
    13. Mullhaupt B,
    14. Dufour JF
    : Treatment of non-alcoholic steatohepatitis patients with vitamin d: A double-blinded, randomized, placebo-controlled pilot study. Scand J Gastroenterol 53(9): 1114-1120, 2018. PMID: 30270688. DOI: 10.1080/00365521.2018.1501091
    OpenUrl
  10. ↵
    1. Calzadilla Bertot L,
    2. Adams LA
    : The natural course of non-alcoholic fatty liver disease. Int J Mol Sci 17(5), 2016. PMID: 27213358. DOI: 10.3390/ijms17050774
  11. ↵
    1. Wong VW,
    2. Adams LA,
    3. de Ledinghen V,
    4. Wong GL,
    5. Sookoian S
    : Noninvasive biomarkers in nafld and nash - current progress and future promise. Nat Rev Gastroenterol Hepatol 15(8): 461-478, 2018. PMID: 29844588. DOI: 10.1038/s41575-018-0014-9
    OpenUrlCrossRef
  12. ↵
    1. Adams JS,
    2. Hewison M
    : Update in vitamin d. J Clin Endocrinol Metab 95(2): 471-478, 2010. PMID: 20133466. DOI: 10.1210/jc.2009-1773
    OpenUrlCrossRefPubMed
  13. ↵
    1. Wobke TK,
    2. Sorg BL,
    3. Steinhilber D
    : Vitamin d in inflammatory diseases. Front Physiol 5(244), 2014. PMID: 25071589. DOI: 10.3389/fphys.2014.00244
  14. ↵
    1. Wang H,
    2. Chen W,
    3. Li D,
    4. Yin X,
    5. Zhang X,
    6. Olsen N,
    7. Zheng SG
    : Vitamin d and chronic diseases. Aging Dis 8(3): 346-353, 2017. PMID: 28580189. DOI: 10.14336/AD.2016.1021
    OpenUrl
  15. ↵
    1. Stokes CS,
    2. Volmer DA,
    3. Grunhage F,
    4. Lammert F
    : Vitamin d in chronic liver disease. Liver Int 33(3): 338-352, 2013. PMID: 23402606. DOI: 10.1111/liv.12106
    OpenUrlCrossRefPubMed
  16. ↵
    1. Barchetta I,
    2. Angelico F,
    3. Del Ben M,
    4. Baroni MG,
    5. Pozzilli P,
    6. Morini S,
    7. Cavallo MG
    : Strong association between non alcoholic fatty liver disease (nafld) and low 25(oh) vitamin d levels in an adult population with normal serum liver enzymes. BMC Med 9(85): 1741-7015, 2011. PMID: 21749681. DOI: 10.1186/1741-7015-9-85
    OpenUrl
    1. Barchetta I,
    2. Carotti S,
    3. Labbadia G,
    4. Gentilucci UV,
    5. Muda AO,
    6. Angelico F,
    7. Silecchia G,
    8. Leonetti F,
    9. Fraioli A,
    10. Picardi A,
    11. Morini S,
    12. Cavallo MG
    : Liver vitamin d receptor, cyp2r1, and cyp27a1 expression: Relationship with liver histology and vitamin d3 levels in patients with nonalcoholic steatohepatitis or hepatitis c virus. Hepatology 56(6): 2180-2187, 2012. PMID: 22753133. DOI: 10.1002/hep.25930
    OpenUrlCrossRefPubMed
    1. Dasarathy J,
    2. Periyalwar P,
    3. Allampati S,
    4. Bhinder V,
    5. Hawkins C,
    6. Brandt P,
    7. Khiyami A,
    8. McCullough AJ,
    9. Dasarathy S
    : Hypovitaminosis d is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int 34(6): 1, 2014. PMID: 24118743. DOI: 10.1111/liv.12312
    OpenUrl
    1. Manco M,
    2. Ciampalini P,
    3. Nobili V
    : Low levels of 25-hydroxyvitamin d(3) in children with biopsy-proven nonalcoholic fatty liver disease. Hepatology 51(6): 2229, 2010. PMID: 20513013. DOI: 10.1002/hep.23724
    OpenUrlPubMed
    1. Nelson JE,
    2. Roth CL,
    3. Wilson LA,
    4. Yates KP,
    5. Aouizerat B,
    6. Morgan-Stevenson V,
    7. Whalen E,
    8. Hoofnagle A,
    9. Mason M,
    10. Gersuk V,
    11. Yeh MM,
    12. Kowdley KV
    : Vitamin d deficiency is associated with increased risk of non-alcoholic steatohepatitis in adults with non-alcoholic fatty liver disease: Possible role for mapk and nf-kappab? Am J Gastroenterol 111(6): 852-863, 2016. PMID: 27002799. DOI: 10.1038/ajg.2016.51
    OpenUrl
    1. Nobili V,
    2. Giorgio V,
    3. Liccardo D,
    4. Bedogni G,
    5. Morino G,
    6. Alisi A,
    7. Cianfarani S
    : Vitamin d levels and liver histological alterations in children with nonalcoholic fatty liver disease. Eur J Endocrinol 170(4): 547-553, 2014. PMID: 24412930. DOI: 10.1530/EJE-13-0609
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Targher G,
    2. Bertolini L,
    3. Scala L,
    4. Cigolini M,
    5. Zenari L,
    6. Falezza G,
    7. Arcaro G
    : Associations between serum 25-hydroxyvitamin d3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 17(7): 517-524, 2007. PMID: 16928437. DOI: 10.1016/j.numecd.2006.04.002
    OpenUrlCrossRefPubMed
  18. ↵
    1. Chung GE,
    2. Kim D,
    3. Kwak MS,
    4. Yang JI,
    5. Yim JY,
    6. Lim SH,
    7. Itani M
    : The serum vitamin d level is inversely correlated with nonalcoholic fatty liver disease. Clin Mol Hepatol 22(1): 146-151, 2016. PMID: 27044765. DOI: 10.3350/cmh.2016.22.1.146
    OpenUrl
  19. ↵
    1. Anty R,
    2. Hastier A,
    3. Canivet CM,
    4. Patouraux S,
    5. Schneck AS,
    6. Ferrari-Panaia P,
    7. Ben-Amor I,
    8. Saint-Paul MC,
    9. Gugenheim J,
    10. Gual P,
    11. Iannelli A,
    12. Tran A
    : Severe vitamin d deficiency is not associated with liver damage in morbidly obese patients. Obes Surg 26(9): 2138-2143, 2016. PMID: 26787197. DOI: 10.1007/s11695-016-2070-y
    OpenUrl
    1. Bril F,
    2. Maximos M,
    3. Portillo-Sanchez P,
    4. Biernacki D,
    5. Lomonaco R,
    6. Subbarayan S,
    7. Correa M,
    8. Lo M,
    9. Suman A,
    10. Cusi K
    : Relationship of vitamin d with insulin resistance and disease severity in non-alcoholic steatohepatitis. J Hepatol 62(2): 405-411, 2015. PMID: 25195551. DOI: 10.1016/j.jhep.2014.08.040
    OpenUrlCrossRefPubMed
    1. Diez Rodriguez R,
    2. Ballesteros Pomar MD,
    3. Calleja Fernandez A,
    4. Calleja Antolin S,
    5. Cano Rodriguez I,
    6. Linares Torres P,
    7. Jorquera Plaza F,
    8. Olcoz Goni JL
    : Vitamin d levels and bone turnover markers are not related to non-alcoholic fatty liver disease in severely obese patients. Nutr Hosp 30(6): 1256-1262, 2014. PMID: 25433106. DOI: 10.3305/nh.2014.30.6.7948
    OpenUrl
  20. ↵
    1. Patel YA,
    2. Henao R,
    3. Moylan CA,
    4. Guy CD,
    5. Piercy DL,
    6. Diehl AM,
    7. Abdelmalek MF
    : Vitamin d is not associated with severity in nafld: Results of a paired clinical and gene expression profile analysis. Am J Gastroenterol 111(11): 1591-1598, 2016. PMID: 27644736. DOI: 10.1038/ajg.2016.406
    OpenUrl
  21. ↵
    1. Ding N,
    2. Liddle C,
    3. Evans RM,
    4. Downes M
    : Hepatic actions of vitamin d receptor ligands: A sunshine option for chronic liver disease? Expert Rev Clin Pharmacol 6(6): 597-599, 2013. PMID: 24164608. DOI: 10.1586/17512433.2013.841078
    OpenUrl
  22. ↵
    1. Duran A,
    2. Hernandez ED,
    3. Reina-Campos M,
    4. Castilla EA,
    5. Subramaniam S,
    6. Raghunandan S,
    7. Roberts LR,
    8. Kisseleva T,
    9. Karin M,
    10. Diaz-Meco MT,
    11. Moscat J
    : P62/sqstm1 by binding to vitamin d receptor inhibits hepatic stellate cell activity, fibrosis, and liver cancer. Cancer Cell 30(4): 595-609, 2016. PMID: 27728806. DOI: 10.1016/j.ccell.2016.09.004
    OpenUrlCrossRef
  23. ↵
    1. Hochrath K,
    2. Stokes CS,
    3. Geisel J,
    4. Pollheimer MJ,
    5. Fickert P,
    6. Dooley S,
    7. Lammert F
    : Vitamin d modulates biliary fibrosis in abcb4-deficient mice. Hepatol Int 8(3): 443-452, 2014. PMID: 25191532. DOI: 10.1007/s12072-014-9548-2
    OpenUrl
  24. ↵
    1. Beilfuss A,
    2. Sowa JP,
    3. Sydor S,
    4. Beste M,
    5. Bechmann LP,
    6. Schlattjan M,
    7. Syn WK,
    8. Wedemeyer I,
    9. Mathe Z,
    10. Jochum C,
    11. Gerken G,
    12. Gieseler RK,
    13. Canbay A
    : Vitamin d counteracts fibrogenic tgf-beta signalling in human hepatic stellate cells both receptor-dependently and independently. Gut 64(5): 791-799, 2015. PMID: 25134788. DOI: 10.1136/gutjnl-2014-307024
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Su D,
    2. Nie Y,
    3. Zhu A,
    4. Chen Z,
    5. Wu P,
    6. Zhang L,
    7. Luo M,
    8. Sun Q,
    9. Cai L,
    10. Lai Y,
    11. Xiao Z,
    12. Duan Z,
    13. Zheng S,
    14. Wu G,
    15. Hu R,
    16. Tsukamoto H,
    17. Lugea A,
    18. Liu Z,
    19. Pandol SJ,
    20. Han YP
    : Vitamin d signaling through induction of paneth cell defensins maintains gut micro-biota and improves metabolic disorders and hepatic steatosis in animal models. Front Physiol 7(498), 2016. PMID: 27895587. DOI: 10.3389/fphys.2016.00498
  26. ↵
    1. Su YB,
    2. Li TH,
    3. Huang CC,
    4. Tsai HC,
    5. Huang SF,
    6. Hsieh YC,
    7. Yang YY,
    8. Huang YH,
    9. Hou MC,
    10. Lin HC
    : Chronic calcitriol supplementation improves the inflammatory profiles of circulating monocytes and the associated intestinal/adipose tissue alteration in a diet-induced steatohepatitis rat model. PLoS One 13(4), 2018. PMID: 29684027. DOI: 10.1371/journal.pone.0194867
  27. ↵
    1. Kong M,
    2. Zhu L,
    3. Bai L,
    4. Zhang X,
    5. Chen Y,
    6. Liu S,
    7. Zheng S,
    8. Pandol SJ,
    9. Han YP,
    10. Duan Z
    : Vitamin d deficiency promotes nonalcoholic steatohepatitis through impaired enterohepatic circulation in animal model. Am J Physiol Gastrointest Liver Physiol 307(9): 11, 2014. PMID: 25214402. DOI: 10.1152/ajpgi.00427.2013
    OpenUrl
  28. ↵
    1. Han H,
    2. Cui M,
    3. You X,
    4. Chen M,
    5. Piao X,
    6. Jin G
    : A role of 1,25(oh)2d3 supplementation in rats with nonalcoholic steatohepatitis induced by choline-deficient diet. Nutr Metab Cardiovasc Dis 25(6): 556-561, 2015. PMID: 25843661. DOI: 10.1016/j.numecd.2015.02.011
    OpenUrl
  29. ↵
    1. Feldstein AE,
    2. Wieckowska A,
    3. Lopez AR,
    4. Liu YC,
    5. Zein NN,
    6. McCullough AJ
    : Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology 50(4): 1072-1078, 2009. PMID: 19585618. DOI: 10.1002/hep.23050
    OpenUrlCrossRefPubMed
  30. ↵
    1. Chow EC,
    2. Magomedova L,
    3. Quach HP,
    4. Patel R,
    5. Durk MR,
    6. Fan J,
    7. Maeng HJ,
    8. Irondi K,
    9. Anakk S,
    10. Moore DD,
    11. Cummins CL,
    12. Pang KS
    : Vitamin d receptor activation down-regulates the small heterodimer partner and increases cyp7a1 to lower cholesterol. Gastroenterology 146(4): 1048-1059, 2014. PMID: 24365583. DOI: 10.1053/j.gastro.2013.12.027
    OpenUrlCrossRefPubMed
  31. ↵
    1. Li R,
    2. Guo E,
    3. Yang J,
    4. Li A,
    5. Yang Y,
    6. Liu S,
    7. Liu A,
    8. Jiang X
    : 1,25(oh)2 d3 attenuates hepatic steatosis by inducing autophagy in mice. Obesity 25(3): 561-571, 2017. PMID: 28145056. DOI: 10.1002/oby.21757
    OpenUrl
  32. ↵
    1. Yin Y,
    2. Yu Z,
    3. Xia M,
    4. Luo X,
    5. Lu X,
    6. Ling W
    : Vitamin d attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism. Eur J Clin Invest 42(11): 1189-1196, 2012. PMID: 22958216. DOI: 10.1111/j.1365-2362.2012.02706.x
    OpenUrlCrossRefPubMed
  33. ↵
    1. Geldenhuys S,
    2. Hart PH,
    3. Endersby R,
    4. Jacoby P,
    5. Feelisch M,
    6. Weller RB,
    7. Matthews V,
    8. Gorman S
    : Ultraviolet radiation suppresses obesity and symptoms of metabolic syndrome independently of vitamin d in mice fed a high-fat diet. Diabetes 63(11): 3759-3769, 2014. PMID: 25342734. DOI: 10.2337/db13-1675
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Nakano T,
    2. Cheng YF,
    3. Lai CY,
    4. Hsu LW,
    5. Chang YC,
    6. Deng JY,
    7. Huang YZ,
    8. Honda H,
    9. Chen KD,
    10. Wang CC,
    11. Chiu KW,
    12. Jawan B,
    13. Eng HL,
    14. Goto S,
    15. Chen CL
    : Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol 55(2): 415-425, 2011. PMID: 21184788. DOI: 10.1016/j.jhep.2010.11.028
    OpenUrlCrossRefPubMed
  35. ↵
    1. Roth CL,
    2. Elfers CT,
    3. Figlewicz DP,
    4. Melhorn SJ,
    5. Morton GJ,
    6. Hoofnagle A,
    7. Yeh MM,
    8. Nelson JE,
    9. Kowdley KV
    : Vitamin d deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. Hepatology 55(4): 1103-1111, 2012. PMID: 21994008. DOI: 10.1002/hep.24737
    OpenUrlCrossRefPubMed
  36. ↵
    1. Wang H,
    2. Zhang Q,
    3. Chai Y,
    4. Liu Y,
    5. Li F,
    6. Wang B,
    7. Zhu C,
    8. Cui J,
    9. Qu H,
    10. Zhu M
    : 1,25(oh)2d3 downregulates the toll-like receptor 4-mediated inflammatory pathway and ameliorates liver injury in diabetic rats. J Endocrinol Invest 38(10): 1083-1091, 2015. PMID: 25906757. DOI: 10.1007/s40618-015-0287-6
    OpenUrlCrossRef
  37. ↵
    1. Bozic M,
    2. Guzman C,
    3. Benet M,
    4. Sanchez-Campos S,
    5. Garcia-Monzon C,
    6. Gari E,
    7. Gatius S,
    8. Valdivielso JM,
    9. Jover R
    : Hepatocyte vitamin d receptor regulates lipid metabolism and mediates experimental diet-induced steatosis. J Hepatol 65(4): 748-757, 2016. PMID: 27245430. DOI: 10.1016/j.jhep.2016.05.031
    OpenUrl
  38. ↵
    1. Ding N,
    2. Yu RT,
    3. Subramaniam N,
    4. Sherman MH,
    5. Wilson C,
    6. Rao R,
    7. Leblanc M,
    8. Coulter S,
    9. He M,
    10. Scott C,
    11. Lau SL,
    12. Atkins AR,
    13. Barish GD,
    14. Gunton JE,
    15. Liddle C,
    16. Downes M,
    17. Evans RM
    : A vitamin d receptor/smad genomic circuit gates hepatic fibrotic response. Cell 153(3): 601-613, 2013. PMID: 23622244. DOI: 10.1016/j.cell.2013.03.028
    OpenUrlCrossRefPubMed
  39. ↵
    1. Chun RF,
    2. Peercy BE,
    3. Orwoll ES,
    4. Nielson CM,
    5. Adams JS,
    6. Hewison M
    : Vitamin d and dbp: The free hormone hypothesis revisited. J Steroid Biochem Mol Biol 144: 132-137, 2014. PMID: 24095930. DOI: 10.1016/j.jsbmb.2013.09.012
    OpenUrlCrossRefPubMed
  40. ↵
    1. Olerod G,
    2. Hulten LM,
    3. Hammarsten O,
    4. Klingberg E
    : The variation in free 25-hydroxy vitamin d and vitamin d-binding protein with season and vitamin d status. Endocr Connect 6(2): 111-120, 2017. PMID: 28179376. DOI: 10.1530/EC-16-0078
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Lee SJ,
    2. Kang JH,
    3. Iqbal W,
    4. Kwon OS
    : Proteomic analysis of mice fed methionine and choline deficient diet reveals marker proteins associated with steatohepatitis. PLoS One 10(4), 2015. PMID: 25849376. DOI: 10.1371/journal.pone.0120577
  42. ↵
    1. Adams LA,
    2. White SW,
    3. Marsh JA,
    4. Lye SJ,
    5. Connor KL,
    6. Maganga R,
    7. Ayonrinde OT,
    8. Olynyk JK,
    9. Mori TA,
    10. Beilin LJ,
    11. Palmer LJ,
    12. Hamdorf JM,
    13. Pennell CE
    : Association between liver-specific gene polymorphisms and their expression levels with nonalcoholic fatty liver disease. Hepatology 57(2): 590-600, 2013. PMID: 23213074. DOI: 10.1002/hep.26184
    OpenUrlCrossRefPubMed
  43. ↵
    1. Jamka M,
    2. Arslanow A,
    3. Bohner A,
    4. Krawczyk M,
    5. Weber SN,
    6. Grunhage F,
    7. Lammert F,
    8. Stokes CS
    : Effects of gene variants controlling vitamin d metabolism and serum levels on hepatic steatosis. Digestion 97(4): 298-308, 2018. PMID: 29514138. DOI: 10.1159/000485180
    OpenUrl
  44. ↵
    1. Grunhage F,
    2. Hochrath K,
    3. Krawczyk M,
    4. Hoblinger A,
    5. Obermayer-Pietsch B,
    6. Geisel J,
    7. Trauner M,
    8. Sauerbruch T,
    9. Lammert F
    : Common genetic variation in vitamin d metabolism is associated with liver stiffness. Hepatology 56(5): 1883-1891, 2012. PMID: 22576297. DOI: 10.1002/hep.25830
    OpenUrlCrossRefPubMed
  45. ↵
    1. Erbas O,
    2. Solmaz V,
    3. Aksoy D,
    4. Yavasoglu A,
    5. Sagcan M,
    6. Taskiran D
    : Cholecalciferol (vitamin d 3) improves cognitive dysfunction and reduces inflammation in a rat fatty liver model of metabolic syndrome. Life Sci 103(2): 68-72, 2014. PMID: 24727236. DOI: 10.1016/j.lfs.2014.03.035
    OpenUrl
    1. Zhu CG,
    2. Liu YX,
    3. Wang H,
    4. Wang BP,
    5. Qu HQ,
    6. Wang BL,
    7. Zhu M
    : Active form of vitamin d ameliorates non-alcoholic fatty liver disease by alleviating oxidative stress in a high-fat diet rat model. Endocr J 64(7): 663-673, 2017. PMID: 28539530. DOI: 10.1507/endocrj.EJ16-0542
    OpenUrl
    1. Giblin RJ,
    2. Bennett EJ,
    3. Zosky GR,
    4. Dwyer RM
    : The impact of sex and 25(oh)d deficiency on metabolic function in mice. Nutrients 9(9): 985, 2017. PMID: 28880231. DOI: 10.3390/nu9090985
    OpenUrl
    1. Mostafa DK,
    2. Nasra RA,
    3. Zahran N,
    4. Ghoneim MT
    : Pleiotropic protective effects of vitamin d against high fat diet-induced metabolic syndrome in rats: One for all. Eur J Pharmacol 792: 38-47, 2016. PMID: 27789220. DOI: 10.1016/j.ejphar.2016.10.031
    OpenUrl
    1. Jahn D,
    2. Dorbath D,
    3. Kircher S,
    4. Nier A,
    5. Bergheim I,
    6. Lenaerts K,
    7. Hermanns HM,
    8. Geier A
    : Beneficial effects of vitamin d treatment in an obese mouse model of non-alcoholic steatohepatitis. Nutrients 11(1): 77, 2019. PMID: 30609782. DOI: 10.3390/nu11010077
    OpenUrl
    1. Liu XJ,
    2. Wang BW,
    3. Zhang C,
    4. Xia MZ,
    5. Chen YH,
    6. Hu CQ,
    7. Wang H,
    8. Chen X,
    9. Xu DX
    : Vitamin d deficiency attenuates high-fat diet-induced hyperinsulinemia and hepatic lipid accumulation in male mice. Endocrinology 156(6): 2103-2113, 2015. PMID: 25774554. DOI: 10.1210/en.2014-2037
    OpenUrl
    1. Liu L,
    2. Lv G,
    3. Ning C,
    4. Yang YE,
    5. Zhu J
    : Therapeutic effects of 1,25-dihydroxyvitamin d3 on diabetes-induced liver complications in a rat model. Exp Ther Med 11(6): 2284-2292, 2016. PMID: 27284312. DOI: 10.3892/etm.2016.3242
    OpenUrl
    1. Shojaei Zarghani S,
    2. Abbaszadeh S,
    3. Alizadeh M,
    4. Rameshrad M,
    5. Garjani A,
    6. Soraya H
    : The eeffect of metformin combined with calcium-vitamin d3 against diet-induced nonalcoholic fatty liver disease. Adv Pharm Bull 8(1): 97-105, 2018. PMID: 29670844. DOI: 10.15171/apb.2018.012
    OpenUrl
    1. Shojaei Zarghani S,
    2. Soraya H,
    3. Alizadeh M
    : Calcium and vitamin d3 combinations improve fatty liver disease through ampk-independent mechanisms. Eur J Nutr 57(2): 731-740, 2018. PMID: 27988847. DOI: 10.1007/s00394-016-1360-4
    OpenUrl
    1. Kheder R,
    2. Hobkirk J,
    3. Saeed Z,
    4. Janus J,
    5. Carroll S,
    6. Browning MJ,
    7. Stover C
    : Vitamin d3 supplementation of a high fat high sugar diet ameliorates prediabetic phenotype in female ldlr(−/−) and ldlr(+/+) mice. Immun Inflamm Dis 5(2): 151-162, 2017. PMID: 28474500. DOI: 10.1002/iid3.154
    OpenUrl
    1. Abramovitch S,
    2. Sharvit E,
    3. Weisman Y,
    4. Bentov A,
    5. Brazowski E,
    6. Cohen G,
    7. Volovelsky O,
    8. Reif S
    : Vitamin d inhibits development of liver fibrosis in an animal model but cannot ameliorate established cirrhosis. Am J Physiol Gastrointest Liver Physiol 308(2): 11, 2015. PMID: 25214398. DOI: 10.1152/ajpgi.00132.2013
    OpenUrl
    1. Tablas MB,
    2. Goto RL,
    3. Caetano BFR,
    4. dos Santos SAA,
    5. Barbisan LF
    : Vitamin d3 suppresses the early stages of chemically induced hepatocarcinogenesis in rats: A dose-response analysis. Nutrire 43(1): 12, 2018. DOI: 10.1186/s41110-018-0065-2
    OpenUrl
    1. Turner RT,
    2. Aloia RC,
    3. Segel LD,
    4. Hannon KS,
    5. Bell NH
    : Chronic alcohol treatment results in disturbed vitamin d metabolism and skeletal abnormalities in rats. Alcohol Clin Exp Res 12(1): 159-162, 1988. PMID: 3279849. DOI: 10.1111/j.1530-0277.1988.tb00152.x
    OpenUrlCrossRefPubMed
    1. Trepo E,
    2. Ouziel R,
    3. Pradat P,
    4. Momozawa Y,
    5. Quertinmont E,
    6. Gervy C,
    7. Gustot T,
    8. Degre D,
    9. Vercruysse V,
    10. Deltenre P,
    11. Verset L,
    12. Gulbis B,
    13. Franchimont D,
    14. Deviere J,
    15. Lemmers A,
    16. Moreno C
    : Marked 25-hydroxyvitamin d deficiency is associated with poor prognosis in patients with alcoholic liver disease. J Hepatol 59(2): 344-350, 2013. PMID: 23557869. DOI: 10.1016/j.jhep.2013.03.024
    OpenUrl
PreviousNext
Back to top

In this issue

Anticancer Research: 40 (1)
Anticancer Research
Vol. 40, Issue 1
January 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Vitamin D in Preclinical Models of Fatty Liver Disease
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Vitamin D in Preclinical Models of Fatty Liver Disease
ERSIN KARATAYLI, CAROLINE S. STOKES, FRANK LAMMERT
Anticancer Research Jan 2020, 40 (1) 527-534; DOI: 10.21873/anticanres.13981

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Vitamin D in Preclinical Models of Fatty Liver Disease
ERSIN KARATAYLI, CAROLINE S. STOKES, FRANK LAMMERT
Anticancer Research Jan 2020, 40 (1) 527-534; DOI: 10.21873/anticanres.13981
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Vitamin D in Fatty Liver Disease
    • Vitamin D Research in Preclinical Models of Fatty Liver Disease
    • Factors Involved in Vitamin D Metabolism in Experimental Models of Fatty Liver Disease
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Oral Recombinant Methioninase Prevents Nonalcoholic Fatty Liver Disease in Mice on a High Fat Diet
  • Google Scholar

More in this TOC Section

  • Recent Developments Towards the Synthesis of Vitamin D Metabolites
  • The Effect of Various Doses of Oral Vitamin D3 Supplementation on Gut Microbiota in Healthy Adults: A Randomized, Double-blinded, Dose-response Study
  • Review of Recent Advances in Understanding the Role of Vitamin D in Reducing Cancer Risk: Breast, Colorectal, Prostate, and Overall Cancer
Show more Proceedings of the Joint International Symposium “Vitamin D in Prevention and Therapy” and “Biologic Effects of Light”, 5-7 June, 2019 (Homburg/Saar, Germany)

Similar Articles

Keywords

  • Animal models
  • vitamin D
  • Non-alcoholic fatty liver disease
  • non-alcoholic steatohepatitis
  • review
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire